A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C
暂无分享,去创建一个
[1] A. Jaiswal,et al. Disruption of the DT Diaphorase (NQO1) Gene in Mice Leads to Increased Menadione Toxicity* , 1998, The Journal of Biological Chemistry.
[2] A. Jaiswal,et al. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. , 1997, Archives of biochemistry and biophysics.
[3] V. Misra,et al. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. , 1997, Oncology research.
[4] D. Ross,et al. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. , 1996, Molecular pharmacology.
[5] M. Grever,et al. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. , 1996, Journal of the National Cancer Institute.
[6] A. Jaiswal,et al. Non‐enzymatic and enzymatic activation of mitomycin C: Identification of a unique cytosolic activity , 1996, International journal of cancer.
[7] J. Fahey,et al. Chemoprotection against cancer by phase 2 enzyme induction. , 1995, Toxicology letters.
[8] N. Miyata,et al. Initiating activity of quinones in the two-stage transformation of BALB/3T3 cells. , 1995, Carcinogenesis.
[9] Smith Cd,et al. Differential interactions of cytochalasins with P-glycoprotein , 1995 .
[10] J. T. Zilfou,et al. Differential interactions of cytochalasins with P-glycoprotein. , 1995, Oncology Research.
[11] G. Powis,et al. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs. , 1995, Anticancer research.
[12] P. Workman,et al. Unusually marked hypoxic sensitization to indoloquinone E09 and mitomycin C in a human colon‐tumour cell line that lacks DT‐diaphorase activity , 2007, International journal of cancer.
[13] P. Workman,et al. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. , 1994, Oncology research.
[14] D. Ross,et al. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. , 1994, Oncology research.
[15] G. Adams,et al. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? , 1992, Biochemical pharmacology.
[16] P. Workman,et al. DT-diaphorase and cancer chemotherapy. , 1992, Biochemical pharmacology.
[17] R. Kaufman,et al. Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. , 1991, Nucleic acids research.
[18] A. Rauth,et al. DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. , 1991, Carcinogenesis.
[19] A. Dulhanty,et al. Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. , 1991, Cancer research.
[20] D. Nebert,et al. The human dioxin-inducible NAD(P)H: quinone oxidoreductase cDNA-encoded protein expressed in COS-1 cells is identical to diaphorase 4. , 1991, European journal of biochemistry.
[21] D. Ross,et al. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. , 1990, Cancer research.
[22] D. Scudiero,et al. New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.
[23] O. Mcbride,et al. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. , 1990, Biochemistry.
[24] I. Stratford,et al. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. , 1989, International journal of radiation oncology, biology, physics.
[25] J. J. Roberts,et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). , 1988, Biochemical pharmacology.
[26] D W Nebert,et al. Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16. , 1988, The Journal of biological chemistry.
[27] A. Sartorelli. Therapeutic attack of hypoxic cells of solid tumors: presidential address. , 1988, Cancer Research.
[28] B. Teicher,et al. The hypoxic tumor cell: a target for selective cancer chemotherapy. , 1980, Biochemical pharmacology.
[29] W. Szybalski,et al. Mitomycins and Porfiromycin: Chemical Mechanism of Activation and Cross-linking of DNA , 1964, Science.
[30] A. Griffin,et al. Role of the pituitary in N-2-fluorenyldiacetamide carcinogenesis. , 1958, Journal of the National Cancer Institute.